Biogaran

Biogaran company information, Employees & Contact Information

Explore related pages

Related company profiles:

Biogaran a été fondé en 1996, pour répondre spécifiquement au développement d’un nouveau marché encore méconnu : les médicaments génériques. Proposer aux patients des médicaments de qualité à l’efficacité reconnue dont le brevet est tombé dans le domaine public relevait alors d’un nouveau type de savoir-faire que les laboratoires traditionnels ne possédaient pas. Notre savoir-faire est décliné au travers de différentes gammes : des petits maux du quotidien avec la gamme Biogaran Conseil®, aux pathologies plus lourdes avec des médicaments sur ordonnance. Quelle que soit la pathologie, la santé des patients est au cœur des préoccupations de Biogaran et la même rigueur est apportée à l’élaboration de chaque médicament.

Company Details

Employees
555
Founded
-
Address
Colombes
Phone
33155724100
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
COLOMBES
Looking for a particular Biogaran employee's phone or email?

Biogaran Questions

News

Biogaran sale talks renew fears over foreign control of French pharma - RFI

Biogaran sale talks renew fears over foreign control of French pharma RFI

Dentons advises Servier on the sale of Biogaran - Dentons

Dentons advises Servier on the sale of Biogaran Dentons

France: Servier and BC Partners open negotiations for the sale of Biogaran - Investors in Healthcare

France: Servier and BC Partners open negotiations for the sale of Biogaran Investors in Healthcare

Paris court invalidates crucial claim of Bayer’s sorafenib patent - JUVE Patent

Paris court invalidates crucial claim of Bayer’s sorafenib patent JUVE Patent

BC Partners in talks to buy Biogaran from Servier - pehub.com

BC Partners in talks to buy Biogaran from Servier pehub.com

France against Servier selling generics unit Biogaran, PM says - Reuters

France against Servier selling generics unit Biogaran, PM says Reuters

France Might Block Drugmaker Biogaran’s Sale to Foreign Firm - Bloomberg.com

France Might Block Drugmaker Biogaran’s Sale to Foreign Firm Bloomberg.com

Servier, buoyed by high-performance R&D, confirms its 2025 trajectory to achieve its 2030 ambition - Servier

Servier, buoyed by high-performance R&D, confirms its 2025 trajectory to achieve its 2030 ambition Servier

France Threatens To Block Servier Sale Of Biogaran To Outside Owner - Citeline News & Insights

France Threatens To Block Servier Sale Of Biogaran To Outside Owner Citeline News & Insights

Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia® - GlobeNewswire

Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia® GlobeNewswire

Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab) - BioSpace

Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab) BioSpace

Alvotech to Release First Half 2025 Financial Results on August 13, Conference Call Scheduled for August 14 - Quiver Quantitative

Alvotech to Release First Half 2025 Financial Results on August 13, Conference Call Scheduled for August 14 Quiver Quantitative

Servier's generics unit gets manufacturing facility in Nigeria - Fierce Pharma

Servier's generics unit gets manufacturing facility in Nigeria Fierce Pharma

Alvotech to Release First Half 2025 Financial Results and Host Conference Call - Quiver Quantitative

Alvotech to Release First Half 2025 Financial Results and Host Conference Call Quiver Quantitative

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia - GlobeNewswire

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia GlobeNewswire

Novartis faces new setback in French dispute over fingolimod - JUVE Patent

Novartis faces new setback in French dispute over fingolimod JUVE Patent

Judicial Court of Paris halts SPC battle between MSD and generics - JUVE Patent

Judicial Court of Paris halts SPC battle between MSD and generics JUVE Patent

Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami - GlobeNewswire

Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami GlobeNewswire

MSD and generics await CJEU ruling in French SPC battle over Inegy - JUVE Patent

MSD and generics await CJEU ruling in French SPC battle over Inegy JUVE Patent

France’s Servier Acquires Potential Fragile X Drug in $450 Million Deal - Bloomberg.com

France’s Servier Acquires Potential Fragile X Drug in $450 Million Deal Bloomberg.com

Kirkland Advises BC Partners on Entering Exclusive Negotiations to Acquire Biogaran - Legal Desire Media and Insights

Kirkland Advises BC Partners on Entering Exclusive Negotiations to Acquire Biogaran Legal Desire Media and Insights

Alvotech and Teva Announce Filing Acceptance of U.S. - GlobeNewswire

Alvotech and Teva Announce Filing Acceptance of U.S. GlobeNewswire

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewswire

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference GlobeNewswire

Year in review: top patent cases in France 2023 - JUVE Patent

Year in review: top patent cases in France 2023 JUVE Patent

Medicine shortages in France: heavy penalties for 11 laboratories - The Connexion

Medicine shortages in France: heavy penalties for 11 laboratories The Connexion

Indian companies face French barrier for generic deal - Times of India

Indian companies face French barrier for generic deal Times of India

Blood Pressure Medicine: Drugmaker Servier loses EU court fight over pay-for-delay deals - ET HealthWorld

Blood Pressure Medicine: Drugmaker Servier loses EU court fight over pay-for-delay deals ET HealthWorld

Alkem joins $3 bn race for JB Chem as Torrent pauses talks - ET Manufacturing

Alkem joins $3 bn race for JB Chem as Torrent pauses talks ET Manufacturing

Top 10 patent cases in France 2021 - JUVE Patent

Top 10 patent cases in France 2021 JUVE Patent

Biogaran, the French leader in generics, launches in Ivory Coast - Financial Afrik

Biogaran, the French leader in generics, launches in Ivory Coast Financial Afrik

Torrent, Zydus, EQT set to make the cut for $3 bn JB Chemicals buyout - The Economic Times

Torrent, Zydus, EQT set to make the cut for $3 bn JB Chemicals buyout The Economic Times

French Firm Biogaran Acquires Nigeria’s Swipha - Business Post Nigeria

French Firm Biogaran Acquires Nigeria’s Swipha Business Post Nigeria

Biogaran acquires Swipha for local, international expansion - The Guardian Nigeria News

Biogaran acquires Swipha for local, international expansion The Guardian Nigeria News

Biogaran’s CEO see strong potential in generic drugs market in Nigeria - Businessday NG

Biogaran’s CEO see strong potential in generic drugs market in Nigeria Businessday NG

French pharmaceutical company Biogaran acquires Nigeria’s Swipha - Tekedia

French pharmaceutical company Biogaran acquires Nigeria’s Swipha Tekedia

‘The pharmaceutical industry will grow by 10 per cent when the economy rebounds’ - Businessday NG

‘The pharmaceutical industry will grow by 10 per cent when the economy rebounds’ Businessday NG

French firm, Biogaran acquires Nigeria’s Swipha - Vanguard News

French firm, Biogaran acquires Nigeria’s Swipha Vanguard News

French firms eye health sector| Gulf Times - Gulf Times

French firms eye health sector| Gulf Times Gulf Times

Top Biogaran Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant